#	Pagina
attuale pagina	/open-h2020/projects/224197/index.html

Opendata, web and dolomites

EXPERT SIGNED

EXpanding Platforms for Efficacious mRNA Therapeutics

Total Cost €

EC-Contrib. €

Partnership

Views

EXPERT project word cloud

Explore the words cloud of the EXPERT project. It provides you a very rough idea of what is the project "EXPERT" about.

clinical euncl gmp microfluidic designated nanoparticle nanomedicines intratumorally overruled blocks reproducible scaling treatment create technological formulations immunostimulatory possibilities innovation delivering encapsulate therapy ecosystem trial streamlines proof scalable ing formulation first manufacture bench molecule nanop mrnas therapeutics opens qualities precise shelf complexity perform subsequent facilities drug meet off purification industrial nanocarriers regulatory manufactured showing administered predictable optimize group therapies building platforms qbd specifications man mrna cell investigates protected expert progress translation cancer critical materials bedside true thereby storage quality platform patients classified characterization nanomedicine physicochemical paves

Project "EXPERT" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITAIR MEDISCH CENTRUM UTRECHT Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX website: www.umcutrecht.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Total cost	15˙010˙087 €
EC max contribution	14˙931˙337 € (99%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2019
Duration (year-month-day)	from 2019-09-01 to 2024-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITAIR MEDISCH CENTRUM UTRECHT UNIVERSITAIR MEDISCH CENTRUM UTRECHT Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX website: www.umcutrecht.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	coordinator	2˙363˙251.00
2	ETHERNA IMMUNOTHERAPIES ETHERNA IMMUNOTHERAPIES Organization address address: GALILEILAAN 19 city: NIEL postcode: 2845 website: www.etherna.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (NIEL)	participant	5˙229˙000.00
3	SINTEF AS SINTEF AS Organization address address: STRINDVEGEN 4 city: TRONDHEIM postcode: 7034 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (TRONDHEIM)	participant	1˙153˙906.00
4	FUNDACION CIDETEC FUNDACION CIDETEC Organization address address: PASEO MIRAMON 196 PARQUE TECNOLOGICO DE MIRAMON city: SAN SEBASTIAN postcode: 20014 website: www.cidetec.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (SAN SEBASTIAN)	participant	1˙089˙750.00
5	TEL AVIV UNIVERSITY TEL AVIV UNIVERSITY Organization address address: RAMAT AVIV city: TEL AVIV postcode: 69978 website: http://www.tau.ac.il/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (TEL AVIV)	participant	1˙037˙000.00
6	ASTRAZENECA AB ASTRAZENECA AB Organization address address: Vastra Maelarhamnen city: SODERTAELJE postcode: 151 85 website: www.astrazeneca.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (SODERTAELJE)	participant	927˙500.00
7	THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN Organization address address: College Green city: DUBLIN postcode: 2 website: www.tcd.ie contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	participant	755˙805.00
8	KAROLINSKA INSTITUTET KAROLINSKA INSTITUTET Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 website: www.ki.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (STOCKHOLM)	participant	690˙000.00
9	SEMMELWEIS EGYETEM SEMMELWEIS EGYETEM Organization address address: ULLOI UTCA 26 city: BUDAPEST postcode: 1085 website: www.sote.hu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	HU (BUDAPEST)	participant	687˙375.00
10	EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH Organization address address: HEINRICH-HERTZ-ALLEE 1 city: ST INGBERT postcode: 66386 website: www.eurice.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (ST INGBERT)	participant	658˙125.00
11	CYBERNANO CYBERNANO Organization address address: 193 AVENUE PAUL MULLER city: VILLERS-LES-NANCY postcode: 54600 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (VILLERS-LES-NANCY)	participant	339˙625.00

Map

Project objective

The overall objective of EXPERT is to create an off-the-shelf mRNA-delivering nanomedicine platform that is manufactured via a quality-by-design (QbD) approach with precise nanoparticle characterization and specifications that meet the requirements for GMP scaling up and clinical translation. As proof-of-concept we will perform a first-in-man clinical study for an intratumorally administered immunostimulatory mRNA-nanomedicine in cancer patients. The work focuses on the three critical elements of the call “Innovation platforms for advanced therapies of the future” 1. EXPERT investigates mRNAs as therapeutics, which are classified as advanced therapies. 2. By showing proof-of-concept in a clinical trial we aim to meet the technical, industrial and regulatory challenges to develop a mRNA-nanomedicine formulation from bench to bedside. This opens up new treatment possibilities for a large group of cancer patients and paves the way for subsequent formulations strengthening the European advanced therapy R&D. 3. mRNA nanomedicines are a true platform technology. mRNAs are composed of four similar building blocks, resulting in a molecule with predictable qualities. This allows for a platform approach to production, purification, formulation and storage which streamlines the drug development process offering important technological progress in this field. We will encapsulate mRNA into nanocarriers. Thereby, the mRNA is protected and the physicochemical characteristics of the mRNA are overruled by the characteristics of the nanoparticle to enable target cell uptake. We have experience in state-of-the art materials to make mRNA nanomedicines. To address their complexity we will optimize nanoparticle design and manufacture via QbD. We will use microfluidic manufacture as a scalable and reproducible production technology. To characterize and manufacture the mRNA nanomedicines under GMP conditions we will use the EU-ecosystem of designated facilities within EUNCL and NANOP

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXPERT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXPERT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials